Aktien Sensor

Regeneron Pharmaceuticals has made significant strides in key product developments, including FDA approval for Dupixent and consideration for expanding EYLEA HD treatment options.

Regeneron Pharmaceuticals is a biotech powerhouse on the rise, driven by its innovative approach, strong research pipeline, and commitment to emerging therapies.

Regeneron Pharmaceuticals faces a class action lawsuit alleging securities fraud, amidst a webcast and FDA decision on its linvoseltamab therapy, leaving investors on high alert.